GO
Loading...

Bristol-Myers Squibb Co

More

  • BUSINESS-NEWS-SCHEDULE AT 2200 GMT / 5 PM ET Sunday, 16 Nov 2014 | 4:46 PM ET

    WASHINGTON- President Barack Obama defends the transparency of his signature healthcare law after a White House adviser on the reform said the law passed, in part, because of the "stupidity" of American voters. ALLERGAN, ACTAVIS NEAR DEAL, ANNOUNCEMENT AS EARLY AS MONDAY. NEW YORK- Allergan nears a deal to merge with Actavis Plc, with an announcement coming as soon as...

  • Nov 16- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead...

  • Midday movers: Amazon, Macy's, SunPower & more Thursday, 13 Nov 2014 | 1:19 PM ET

    Some of Thursday's midday movers:

  • LONDON, Nov 13- AstraZeneca is developing an antibody treatment to reverse the blood-thinning effect of its heart drug Brilinta in rare emergency situations, such as urgent surgery or in the event of major bleeding. AstraZeneca said on Thursday the experimental antibody product, MEDI2452, was in pre-clinical tests at its MedImmune biotech unit.

  • LONDON, Nov 6- AstraZeneca, which saw off a $118 billion bid from Pfizer in May, said quarterly results showed its standalone strength, while recent U.S. tax changes removed much of the case for a new takeover attempt. Chief Executive Pascal Soriot, who has fought hard to prove AstraZeneca does not need the kind of mega-merger offered by Pfizer, said he would use the...

  • LONDON, Nov 6- AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of generic copies of its Nexium drug in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover bid from Pfizer in May, now expects revenue to grow in low...

  • LONDON, Nov 6- AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of Nexium generics in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover approach from Pfizer in May, now expects revenue to grow slightly this...

  • Gabelli exec's 'crown jewel' picks for US investing Wednesday, 5 Nov 2014 | 2:22 PM ET

    Global pain will mean U.S. gain at least in terms of stock market investing, according to a strongly bullish analysis from Mario Gabelli's team.

  • Midday movers: Aetna, Geron, Loews & more Monday, 3 Nov 2014 | 12:56 PM ET

    Some of Monday's midday movers:

  • Behind the big bearish bet on Bristol-Myers Friday, 31 Oct 2014 | 7:55 AM ET
    File photo: a researcher in a Bristol-Myers Squibb laboratory.

    Shares of Bristol-Myers hit a 13-year high on Thursday. So why was one big trader getting bearish?

  • Cramer Remix: Apologies owed on Wall Street Thursday, 30 Oct 2014 | 7:49 PM ET

    Even after a big move from the Fed, "Mad Money" host Jim Cramer thinks there are some apologies owed to investors.

  • UPDATE 1-FDA panel backs Daiichi's blood thinner Thursday, 30 Oct 2014 | 6:57 PM ET

    Oct 30- A panel of advisers to the U.S. Food and Drug Administration voted 9-1 in favor of approving Japanese drugmaker Daiichi Sankyo Co's blood thinner for use in some patients with atrial fibrillation. According to late-stage trial data submitted by Daiichi, the drug is as effective- and safer than- warfarin, an anticoagulant that has been on the market for more...

  • Cramer: Best-of-breed stock picks circle back Thursday, 30 Oct 2014 | 6:35 PM ET
    A Chipotle Mexican Grill restaurant is shown in New York.

    Jim Cramer announces his best-of-breed stock picks. Those that will always circle back, because success is a part of their DNA.

  • Midday movers: BorgWarner, Kellogg & more Thursday, 30 Oct 2014 | 12:15 PM ET

    Some of Thursday's midday movers:

  • Oct 28- U.S. Food and Drug Administration staff reviewers recommended approval of a 60 mg dose of Daiichi Sankyo Co's blood thinner for some atrial fibrillation patients, but suggested limiting its use to those with abnormal kidney function. The drug, edoxaban, is a once-daily anticoagulant that inhibits Factor Xa, a protein that plays a central role in...

  • Oct 24- Bristol-Myers Squibb Co reported better-than-expected third-quarter results, as sizzling sales of its treatments for blood clots, cancer and arthritis helped offset sharply higher taxes. That compared with $692 million, or 42 cents per share, in the year-earlier period. Bristol-Myers, along with Merck& Co Inc, Roche Holding AG and AstraZeneca Plc are...

  • Early Movers: F, PG, UPS, AMZN, MSFT Friday, 24 Oct 2014 | 8:44 AM ET

    Some of the names on the move ahead of the open.

  • Oct 24- Bristol-Myers Squibb Co reported better-than-expected third-quarter results, fueled by strong sales of its treatments for blood clots, cancer and arthritis. That compared with $692 million, or 42 cents per share, in the year-earlier period. Revenue fell 4 percent to $3.92 billion, largely due to the company's earlier divestiture of diabetes products,...

  • Market on track for strong week; wary of Ebola news Thursday, 23 Oct 2014 | 7:02 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks head into Friday on track for the best weekly performance in 22 months, yet new Ebola fears and other geopolitical headlines could be wild cards.

  • Cramer: Tune in for the most vital earnings week Friday, 17 Oct 2014 | 6:14 PM ET

    Jim Cramer said next week is the most important week of the year for earnings. Find out what stocks he will be focused on.